



Moore et al. Cardiovascular Diabetology 2014, 13:68
http://www.cardiab.com/content/13/1/68ORIGINAL INVESTIGATION Open AccessRapid onset of cardiomyopathy in STZ-induced
female diabetic mice involves the downregulation
of pro-survival Pim-1
Andrew Moore1, Amol Shindikar1, Ingrid Fomison-Nurse1, Federica Riu3, Pujika E Munasinghe1, Thrishila Parshu Ram1,
Pankaj Saxena2,5, Sean Coffey3,6, Richard W Bunton2, Ivor F Galvin2, Michael JA Williams3, Costanza Emanueli4,
Paolo Madeddu4 and Rajesh Katare1*Abstract
Background: Diabetic women are five times more likely to develop congestive heart failure compared with two
fold for men. The underlying mechanism for this gender difference is not known. Here we investigate the
molecular mechanisms responsible for this female disadvantage and attempt safeguarding cardiomyocytes viability
and function through restoration of pro-survival Pim-1.
Methods and Results: Diabetes was induced by injection of streptozotocin in CD1 mice of both genders.
Functional and dimensional parameters measurement using echocardiography revealed diastolic dysfunction in
female diabetic mice within 8 weeks after STZ-induced diabetes. This was associated with significant downregulation
of pro-survival Pim-1 and upregulation of pro-apoptotic Caspase-3, microRNA-1 and microRNA-208a. Male diabetic
mice did not show any significant changes at this time point (P < 0.05 vs. female diabetic). Further, the onset of
ventricular remodelling was quicker in female diabetic mice showing marked left ventricular dilation, reduced
ejection fraction and poor contractility (P < 0.05 vs. male diabetic at 12 and 16 weeks of STZ-induced diabetes).
Molecular analysis of samples from human diabetic hearts confirmed the results of pre-clinical studies, showing
marked downregulation of Pim-1 in the female diabetic heart (P < 0.05 vs. male diabetic). Finally, in vitro restoration
of Pim-1 reversed the female disadvantage in diabetic cardiomyocytes.
Conclusions: We provide novel insights into the molecular mechanisms behind the rapid onset of cardiomyopathy in
female diabetics. These results suggest the requirement for the development of gender-specific treatments for diabetic
cardiomyopathy.
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Diabetic cardiomyopathy, a common complication in
people with diabetes, deserves special clinical attention be-
cause of its insidious onset, relatively rapid evolution from
diastolic to global cardiac dysfunction, [1-3] and very poor
outcome once heart failure (HF) manifests [4,5].
Cardiac complications of diabetes are prevalent in
women. In fact, while non-diabetic women are relatively
protected from cardiovascular disease, this advantage is* Correspondence: rajesh.katare@otago.ac.nz
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unless otherwise stated.lost in diabetes [6]. In the Framingham study, the re-
ported incidence of symptomatic HF was 2.4-fold higher
in men and 5.0-fold higher in women with diabetes
compared to their non-diabetic peers, [7] a finding con-
firmed by several other studies [8-10]. Furthermore, dia-
betic women have significantly higher mortality after
myocardial infarction than diabetic men [11]. A gender
difference was also noted for pre-clinical diabetic cardio-
myopathy. In a series of 100 adults (44% females) with-
out previous evidence of heart disease, echocardiography
showed the presence of diabetic cardiomyopathy in 48%
of patients, with female gender being one of the stron-
gest predictors of cardiac remodelling [12]. In anotherLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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T1D, abnormalities in left ventricular dimensions and
myocardial relaxation were reported, with the girls clearly
being more affected than boys [13]. The reason for this
global “female disadvantage” in diabetes remains largely
unknown. Studies in animal models helped to elucidate
potential pathogenic mechanisms of cardiomyopathy, but
not to explain the interaction between gender and dia-
betes, as most available information derives from investi-
gations performed in male rodents [14]. Hence, a deeper
understanding of gender-related targets for stratified ther-
apy is needed.
Recent studies from us [15-17] and others [18,19]
have unveiled a spectrum of molecular mechanisms in-
volved in the development of diabetic cardiomyopathy.
We hypothesize that these molecular changes would
appear much earlier and develop faster in the female
diabetics, leading to the rapid development of cardiac
dysfunction. We also propose to exploit this new know-
ledge for gender-specific treatment of diabetic cardiomyop-
athy. To this aim, we have performed a time course study
comparing male and female diabetic mice from early to late
stages of cardiomyopathy. Echocardiography follow-up was
coupled with investigation of molecular targets. We also
verified the molecular mechanisms in biopsies from human
hearts. Finally, we applied a rescue approach which demon-
strates for the first time the importance of Pim-1 in gender
disparity of diabetic cardiomyopathy.
Materials and methods
Ethics
Investigation conforms to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996) and with approval of the Animal Ethical Commit-
tees of the University of Otago, New Zealand, British
Home Office and the University of Bristol, United King-
dom. Human right atrial tissue samples were collected
from the patients undergoing on-pump coronary artery
bypass graft surgery after written consent which con-
forms with the principles outlined in the Declaration of
Helsinki and was approved by the Human and Disability
Ethics Committee of New Zealand.
In vivo studies
Mouse model of STZ-induced diabetes
Diabetes was induced in CD1 mice of both genders
(Charles River, UK and HTRU, NZ) by injection of strep-
tozotocin (STZ; 40 mg/kg body weight i.p. per day for 5
days). Age-matched animals that received STZ-vehicle
served as non-diabetic controls [17,20]. Hyperglycemia
was confirmed by measuring glucose levels in blood and
urine. No difference was observed between genders at
any time point of the study (Additional file 1: Figure S1).In vivo functional measurements
Echocardiography
Functional and dimensional parameters were measured
at 4, 8, 12, 16 and 32 weeks after STZ-induced diabetes
using a high-frequency echocardiography system (Vivid
E9, GE Health Sciences, New Zealand) (n = 8 mice per
group). Briefly, mice were anesthetized using tribromo-
ethanol (Avertin) and transferred to an imaging stage
equipped with a warming pad for controlled mainten-
ance of mouse body temperature at 37°C. Standard B
mode (2D) images of the heart and pulsed Doppler im-
ages of the mitral valve inflow (to estimate the diastolic
dysfunction) were acquired. Thickness of the left ven-
tricle anterior wall (LVAW) during systole (LVAWs) and
diastole (LVAWd) was measured at the level of the papil-
lary muscles in parasternal short axis at end-systole and
end-diastole. LV ejection fraction (LVEF), end systolic
volume (ESV) and end diastolic volume (EDV) were de-
termined as described earlier [15,21-24].
Measurement of intra-ventricular pressure
Direct measurement of intra-ventricular pressure and vol-
ume was done immediately after the echocardiographic
measurements at 12, 20 and 32 week time point using a
high-fidelity 1.4F transducer tipped catheter (Millar In-
struments, Houston, TX, USA) as explained earlier. In
brief, the catheter was inserted into the right carotid artery
and slowly advanced into the heart, where its position was
confirmed by the rapid deflection of the diastolic pressure
wave without any change in systolic pressure. After 5 mi-
nutes stabilization period, data were collected including
the heart rate (HR), LV end systolic pressure (LVESP), LV
end-diastolic pressure (LVEDP) and maximal rates of LV
pressure rise (dP/dtmax) and fall (dP/dtmin). At the end of
the measurement, samples were collected from left ven-
tricle for western blotting and RT-PCR analysis.
TUNEL staining
Apoptosis was quantified on LV cryosections (5 μm) by
the terminal deoxynucleotidyltransferase (TdT)-mediated
dUTP nick-end labeling (TUNEL) technique (in situ cell
death detection kit Fluorescein, Roche applied science,
USA). Following treatment of slides with proteinase K
(20 μg/ml, 30 min at 37°C), TUNEL assay was performed
according to the manufacturer’s instruction. The same sec-
tions were then stained with DAPI to recognize nuclei and
α-sarcomeric actin to recognize cardiomyocytes. Twenty
fields were randomly evaluated in each section at X400
magnification. The fraction of TUNEL positive nuclei over
total cardiomyocyte nuclei was then calculated [17,25].
Western blotting
The left ventricular tissue was homogenized in ice-cold
RIPA buffer and protein concentration was measured using
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the right atrial appendage of the diabetic and non-
diabetic patients undergoing coronary artery bypass
graft surgery for ischemic heart disease. Western blot
analysis was done following separation of whole tissue
(50 μg)/cell extracts (20 μg) on SDS-polyacrylamide gels.
Proteins were transferred to polyvinylidene difluoride
membranes (PVDF, Amersham-Pharmacia) and probed
with the following antibodies: Pim-1 (Cell Signaling,
1:1000), Ser473- phospho-Akt (Cell Signaling, 1:1000),
Akt (Cell Signaling, 1:1000), Bcl-2 (Cell Signaling, 1:1000),
Total Caspase-3 (Cell Signaling, 1:1000), cleaved-caspase-
3 (Cell Signaling, 1:1000) and Receptor interacting protein
(RIP) kinase (Life Technologies, 1:1000). Actin (Cell
Signaling, 1:1000) was used as loading control. For de-
tection, secondary antibody goat anti-rabbit 680nm or
anti-mouse 800 nm (both from Thermo Scientific, 1:15000)
or HRP-conjugated anti-rabbit or mouse were used,
followed by imaging either using the fluorescence im-
aging system (Odyssey) or chemiluminescence reaction
(ECL, Amersham Pharmacia). Density of the bands was
analyzed using Image-J (NIH, USA) software, inconsist-
ency in the actin between the samples was normalized
as described earlier [26] and data expressed in fold changes.
RT PCR
Total RNA were extracted from either mice LV samples or
human right atrial appendage using commercially avail-
able kit (Qiagen). Twenty nanograms of total RNA was re-
verse transcribed followed by amplification using specific
primers against microRNA (miR)-1 and miR-208a. U6
was used as the internal control (all the primers and kits
from Life Technologies). Of note, the homology of miR
expression patterns between human and mice has been
well established [27]. For quantification, the amount of
miR was normalized to the amount of U6 miR using the
2 −DDCT method. Each reaction was performed in tripli-
cate and repeated 5 times [16].
In vitro studies
We used in vitro cardiomyocytes culture to study the ef-
fect of Pim-1 overexpression on molecular and func-
tional targets.
Isolation and culture of adult mouse cardiomyocytes
Cardiomyocytes were isolated from diabetic and non-
diabetic mice heart of both the gender at 4, 8 and 12
weeks after STZ-induced diabetes as explained earlier
[28,29]. In brief, the heart was quickly removed from the
chest and retrogradely perfused at a constant pressure
and at 37°C, with Ca2+ free KH buffer for 3 minutes,
followed by enzymatic digestion with collagenase type B
(0.5 mg/ml; Boehringer Manheim), collagenase type D
(0.5 mg/ml; Boehringer Manheim), and protease typeXIV (0.02 mg/ml; Sigma) for another 3 minutes. The
heart was then perfused for another 7 minutes in KH
buffer containing enzyme mix and 50 μM Ca2+, after
which the heart was removed, cut in to small chunks
and further digested in a shaker at 60 rpm for 10 mi-
nutes at 37°C in the same enzyme solution. The super-
natant containing the dispersed myocytes was filtered
into a sterilized tube and gently centrifuged at 500 rpm
for 1 minute. The Ca2+ concentration was restored in a
step-wise manner. The final cell pellet was suspended
in minimal essential medium (MEM; Sigma Chemicals)
containing 1.2 mM Ca2+, 2.5% preselected fetal bovine
serum, and 1% penicillin-streptomycin solution (pH
7.35–7.45). Cells were finally plated in the cell culture
dish coated with mouse laminin (Sigma Chemicals) de-
pending on the type of experiment.Transfection with Pim-1 plasmid or anti-miR
Freshly isolated cardiomyocytes from diabetic and non-
diabetic murine hearts of both genders were transfected
either with human Pim-1 plasmid (8 μg/1×106 cells) [15],
or anti-miR-1/208 (50 nM, Life Technologies) using com-
mercially available Lipofectamine 2000 (Life Technologies)
according to the manufacturer’s instructions. Scrambled
sequence was used as control for both the types of expe-
riments. Transfection efficacy was confirmed by staining
the cardiomyocytes with antibody specific to human Pim-
1 plasmid (Abgent, 1:100) as described in our earlier study
[15]. We achieved around 65% transfection efficacy with
this technique (Additional file 1: Figure S2). After 24
hours, the medium was replaced with fresh medium and
after another 48 hours culture cells were used for the ex-
periments [15].
For western blotting, cells were seeded on a 24-well dish
(1×106 cardiomyocytes/well). After transfection period,
cells were homogenized and the resultant proteins were
used for western blotting as above.
For caspase activity assay, 5×103 cells were plated on
96-well dish and underwent similar transfection and
treatment procedure. At the end of treatment, equal
volume of caspase assay reagent was added to the
wells and incubated in dark for 30 minutes at room
temperature. The luminescence was read using Pro-
mega luciferase assay system [16].Statistical analysis
Comparison of multiple groups at different time points
was performed by two-way analysis of variance (ANOVA)
with Bonferroni adjustment considering the two factors
(a) diabetes and (b) gender. Two-group analysis was
performed by Student’s t-test. Values were expressed as
mean±SD. Probability values (P) less than 0.05 were
considered significant.
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Early onset of cardiac dysfunction in female diabetic mice
Diastolic dysfunction
Serial echocardiography measurement showed significant
diastolic dysfunction in female diabetic mice as early as 8
weeks after STZ-induced diabetes, as evidenced by the
marked decrease in the E/A ratio (Figure 1A, P < 0.05 vs.
female non-diabetic). Interestingly, the E/A ratio returned
to non-diabetic levels at 12 weeks. However, with pro-
gression of the disease, the index started to decline again
and remained consistently low from week 16 (Figure 1A).
In contrast, male diabetics did not show any changes in
the E/A ratio until 12 weeks after STZ-induced diabetes
(Figure 1A). Although there was no significant difference
between male and female diabetics at any corresponding
time point, there was a clear trend for the female dia-
betics to have reduced E/A ratio throughout the study
(Figure 1A). In addition, the percentage of change in the
E/A ratio with respect to 4 week time point was
significantly higher in female diabetics (P < 0.05 vs.
male diabetics at 12, 16 and 32 weeks and near significantFigure 1 Rapid onset of cardiomyopathy in STZ-induced female diabe
indexes of left ventricle (LV) function assessed (B, C & D) by the serial echo
least 8 at each time point). LVEF – LV ejection fraction, ESV – LV end systol
means ± SD. Results of pair-wise comparison are illustrated. *P < 0.05, **P <
corresponding time point. #P < 0.05 and ##P < 0.01 vs. male diabetic at corrat 8 weeks compared to male mice, Additional file 1:
Figure S3A). Non-diabetic mice of both genders showed
no significant changes with the age.
Systolic dysfunction
Changes in the systolic function were estimated by serial
measurement of the LVEF. Female diabetics started show-
ing reduction in the LVEF at 12 weeks after STZ-induced
diabetes (Figure 1B, P < 0.05 vs. female non-diabetics),
however, no changes were observed in male diabetics at
this time point. With the progression of the disease, de-
terioration of LVEF was rapid in females compared to
males (Figure 1B and Additional file 1: Figure S3B, P <
0.05 vs. male diabetics at 16 and 20 weeks).
Deterioration of LVEF was associated with marked
dilation of the left ventricle as evidenced by rapid increase
in the end systolic volume (Figure 1C and Additional file
1: Figure S3C) and thinning of anterior wall (Figure 1D &
online Additional file 1: Figure S3D) in female diabetics
compared to male diabetic mice (P < 0.05 vs. male diabetic
at 12, 16 and 20 weeks).tic mice. Line graphs showing the mitral valve flow velocity (A) and
cardiogram at different time points from STZ or STZ-vehicle (n = at
ic volume, LVAWs – LV anterior wall thickness during systole. Values are
0.01 and ***P < 0.001 vs. non-diabetic of corresponding gender at
esponding time point.
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In addition to the echocardiographic measurements, a
Millar catheter was used to directly measure the LV pres-
sure before collecting samples for molecular analysis. As
shown in Figure 2, there was rapid worsening of systolic
and diastolic function in female diabetic as evidenced by
the decrease of LV end systolic (Figure 2A) and increase
of LV end diastolic pressure (Figure 2B) in female dia-
betics at 12 weeks after STZ-induced diabetes (P < 0.05 vs.
female non-diabetic). Maximal (dP/dtmax, Figure 2C) and
minimal (dP/dtmin, Figure 2D) indices of contractility also
started to deteriorate at 12 weeks in female diabetic hearts
(P < 0.05 vs. female non-diabetic), although it should be
noted that dP/dt can be affected by low intracavitary
pressure alone. With the progression of the disease,
contractile parameters showed consistent deterioration.
Male diabetic mice did not show any significant differ-
ence at 12 week time point (Figure 2). Although the
contractility started to decline from 20 weeks in male
diabetics (P < 0.05 vs. male non-diabetic), the rate of de-
terioration for all the contractile parameters was slower
than in the female diabetics (P < 0.05 at 12, 20 and 32
weeks for all the (Figure 2).
These functional data not only demonstrate the early
onset of cardiomyopathy in female diabetic mice, butFigure 2 Reduced contractility of STZ-induced female diabetic heart.
diastolic pressure (LVEDP, B), maximum (C) and minimum (D) rates of deve
weeks after STZ-induced diabetes (n = at least 8 at each time point). Values
*P < 0.05, **P < 0.01 and ***P < 0.001 vs. non-diabetic of corresponding gen
diabetic at corresponding time point.also confirms the rapid evolution of the disease in
females.
Early downregulation of pro-survival molecular pathway
in female diabetics
Our earlier studies have demonstrated that molecular
changes occurring early in the diabetic heart form the basis
for the development of structural and functional changes at
later stage [15,16]. To investigate if the key molecular
changes occur earlier in female diabetics, we performed
western blotting of cell survival and pro-apoptotic proteins
at 4, 8, 12 and 32 weeks after STZ-induced diabetes. Results
show the marked downregulation of the pro-survival pro-
tein Pim-1 (Figure 3A) in female diabetic mice as early as 4
weeks after STZ-induced diabetes, which was associated
with marked upregulation of pro-apoptotic protein cleaved
Caspase-3 (Figure 3B), while no significant change was ob-
served in male diabetics at this time point (P < 0.05 vs. fe-
male non-diabetic and male diabetic). This was further
confirmed by the histological analysis of the cardiac tissue,
which demonstrated marked increase in the TUNEL posi-
tive cardiomyocytes in the female diabetic heart starting
from 4 weeks of STZ-induced diabetes (P < 0.05 vs male
diabetic at 4, 8 and 12 weeks, Figure 3C) . To understand if
diabetes also increases the necrotic cell death, we measuredBar graphs showing LV end systolic pressure (LVEDP, A), LV end
loped pressure (dP/dt) among the study groups at 12, 20 and 32
are means ± SD. Results of pair-wise comparison are illustrated.
der at corresponding time point. #P < 0.05 and ##P < 0.01 vs. male
Figure 3 Rapid deterioration of survival proteins and increased apoptosis in STZ-induced female diabetic heart. A-B and D-E representative
blots and bar graphs showing the levels of Pim-1 (A), total and cleaved Caspase-3 (B), pAkt/Akt (D) and Bcl-2 (E) in hearts of diabetic and non-diabetic
hearts of both the genders at different time points after induction of diabetes (n = 6 at each time point). C representative immunofluorescence image
showing TUNEL positive cardiomyocytes at 12 weeks after STZ-induced diabetes. Quantitative bar graphs showing the percentage of TUNEL positive
cardiomyocytes at different time points after induction of diabetes (n = 6 at each time point). F-G Bar graphs showing the expression level of miR-1
(F) and miR-208 (G) in study groups (n = 5 at each time point). Values are means ± SD. Results of pair-wise comparison are illustrated. *P < 0.05, **P < 0.01
and ***P < 0.001 vs. non-diabetic of corresponding gender at corresponding time point. #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. male diabetic
at corresponding time point.
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activation promotes necrosis [30]. While there was no
change in the RIP expression at 4, 8 and 12 weeks after
STZ-induced diabetes, there was significant increases at 32
weeks, with no marked difference between male and female
diabetic hearts (Additional file 1: Figure S4). These data
suggest that apoptosis is the major form of cell death in the
early stages of diabetic cardiomyopathy.
Other pro-survival proteins such as Akt (Figure 3D) and
Bcl-2 (Figure 3E) started to decrease at 12 weeks in female
diabetics (P < 0.05 vs. female non-diabetic). While male dia-
betics also showed modulation of the cell survival proteins
at 12 weeks, the changes were less profound than in female
diabetics (P < 0.05, Figure 3A and B, D and E). Gender-
associated differences were lost in 32 weeks old diabetic
mice, which showed equal deterioration of pro-survival
proteins (Figure 3A and B, D and E). These data indicate
that Pim-1 precedes the deterioration of other protective
factors during the development of cardiomyopathy. For this
reason, we next focused on modulators of Pim-1 expression.
MicroRNAs (miRs) are recently gaining interest due to
their crucial role in post-transcriptional regulation of car-
diac function [31]. Literature search and online target pre-
diction tools (Target Scan and Pictar Scan) revealed miR-1
and miR-208a as possible inhibitors of Pim-1 expression
[15,17,32]. Here, we confirmed that female diabetic hearts
more abundantly express miR-1 (Figure 3F) and miR-208a
(Figure 3G) at 4 weeks after STZ-induced diabetes, with
further increases during evolution of cardiomyopathy
(P < 0.01 vs. female non-diabetic). Male diabetic hearts
also show a significant upregulation of both the miRs,
although the percentage change was initially less than
that of female diabetic hearts (Figure 3F and G, P < 0.05).
Interestingly, gender-associated differences in miR expres-
sion disappeared with the progression of the disease with
both male and female diabetics showing no difference at 12
weeks after STZ-induced diabetes (Figure 3F and G).
These data suggested that activation of miRs could be
the earliest modulators of the downregulation of Pim-1.
Downregulation of Pim-1 in diabetic human hearts
To further investigate the involvement of Pim-1 in clinical
settings, we measured its protein expression in the right
atrial appendage samples of diabetic and non-diabetic pa-
tients undergoing coronary artery bypass graft surgery for
ischemic heart disease. No difference was found in general
clinical parameters among the study groups except for the
level of glycosylated haemoglobin A1c (HbA1c) which was
higher in the diabetic group of both genders (Additional
file 1: Table S1). As shown in the Figure 4A, while both
male and female diabetics demonstrate a marked decrease
in the level of Pim-1, the percentage of decrease with re-
spect to the respective non-diabetic groups was higher
in females than males (Figure 4A, P < 0.05). To ourknowledge, this is the first study to demonstrate the
downregulation of Pim-1 in human diabetic hearts. Akt
was decreased (Figure 4B) and miR-1 (Figure 4C) and
miR-208 (Figure 4D) was increased in both the diabetic
groups with no significant difference between genders,
although there was a trend for increased levels of miR-1
in female diabetics (Figure 4C). There was no marked
difference in the contractility parameter (LV ejection
fraction) among the study groups, as all the patients re-
cruited in this study had preserved ejection fraction. Al-
though not significant, E/A ratio was at the lower level
in female diabetics (Additional file 1: Table S1).
Rescuing Pim-1 defect improves the survival of cardio-
myocytes from diabetic female hearts
Finally, we verified if restoration of Pim-1 levels could im-
prove the survival of female diabetic cardiomyocytes. To
this aim, cardiomyocytes isolated from diabetic and non-
diabetic mice at 12 weeks after STZ-induced diabetes were
transfected with either hPim-1 plasmid or anti-miR-1/
208a. The twelve week time point was decided due to the
prominence of systolic dysfunction and significant mo-
lecular changes occurring at this time point in female dia-
betic mice. Caspase-3/7 activity assay showed significant
increase in the level of apoptosis in both male and female
diabetic cardiomyocytes (Figure 5A and E), however fe-
male diabetic cardiomyocytes showed much enhanced
apoptotic activity and downregulation of Pim-1 (Figure 5B
and D) and Bcl-2 (Figure 5C). Transfection with Pim-1
(Figure 5A-C) or anti-miR-1/208a (Figure 5D-E) rescued
Pim-1 expression in both the male and female diabetic
cardiomyocytes (Figure 5B and Figure 5D, P < 0.05 vs.
scramble). Importantly, this was associated to restoration
of survival signalling, i.e. Bcl-2 (Figure 5C) and de-
crease in the apoptotic cell death (Caspase-3/7 activity,
Figure 5A&E). No change was observed in the expres-
sion levels of Akt (data not shown).
Discussion
This study provides first molecular evidence for a gender-
specific progression of diabetic cardiomyopathy. Using a
mouse model, we measured functional, structural and mo-
lecular changes in the heart at different time points after
STZ-induced diabetes. We found that the onset of cardiac
dysfunction was more rapid and severe in diabetic females
compared to males. This was associated with gender-
specific LV dilation, which occurred earlier in diabetic fe-
males than males. We also demonstrate that early down-
regulation of pro-survival protein Pim-1 plays a major role
in accelerating the progression of cardiomyopathy in
female diabetics through upregulation of miR-1 and 208a.
In vitro restoration of Pim-1 levels either through direct
overexpression of Pim-1 or inhibition of miR-1 and 208a
reverted this “female disadvantage” in the diabetic
Figure 4 Pim-1 downregulated in human diabetic heart. A-B representative blots and bar graphs showing the levels of Pim-1 (A) and
pAkt/Akt (B) in right atrial appendage samples collected from diabetic and non-diabetic patients undergoing on-pump coronary artery bypass
graft surgery. C-D. Bar graphs showing the expression level of miR-1 (C) and miR-208a (D) in diabetic and non-diabetic human heart. n = at least
7 in each group. ND – non-diabetic; D – Diabetic. Values are means ± SD. **P < 0.01 and ***P < 0.001 vs. non-diabetic of corresponding gender.
#P < 0.05 vs. male diabetic.
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tissue samples from the human diabetic hearts also
showed marked downregulation of Pim-1 in diabetic
females.
Diastolic dysfunction is the earliest clinical sign of dia-
betic cardiomyopathy, followed by progression to systolic
dysfunction [33]. Female diabetic mice showed marked
diastolic dysfunction within 8 weeks of STZ-induced dia-
betes in our study, however, this was lost at 12 weeks. Dia-
stolic dysfunction is usually associated with a decline in
the E/A ratio [21], but this ratio can pseudo-normalise
with progression into severe diastolic dysfunction [34]. In
such cases, an increase in the end diastolic pressure can
restrict the contribution of atrial contraction to LV filling
[34]. Moreover, pseudo-normal or restrictive filling pat-
terns are related to progressive LV dilation and predict
cardiac death after a first MI [35]. Consistently, our echo-
cardiography data showed LV dilation and thinning of the
anterior LV wall associated with increased end diastolic
pressure and decreased dP/dtmin in female mice at 12weeks of STZ-induced diabetes, suggesting the exacerba-
tion of diastolic dysfunction in female diabetic mice.
While our study demonstrated early onset of cardio-
myopathy in female diabetics, Ceylan-Isik et al. reported
that cardiomyocytes isolated from the female diabetic
hearts were better protected than the cardiomyocytes
from male diabetic hearts [36]. Similarly, cardiomyocytes
isolated from young female diabetic mice by Zhang et al.
exhibited normal contractile function [37]. Although
these results are in contrast to our findings, the differ-
ence could be attributed mainly to the different experi-
mental conditions. We used an in vivo model reflecting
near clinical settings, while the above-mentioned studies
used isolated cardiomyocytes. In addition, factors such
as cell death and myocardial fibrosis, which play a major
role in the development of cardiac dysfunction would
not affect the results in in vitro settings.
We and others have shown that selected molecular al-
terations occur early in the diabetic heart which forms the
basis for the development of structural changes [17,18,29].
Figure 5 Restoration of Pim-1 levels reverted female disadvantage. A bar graphs showing the levels of activated caspase-3/7. B-C representative
blots and bar graphs showing the levels of Pim-1 (B) and Bcl-2 (C) in the isolated and cultured cardiomyocytes over expressed with either Pim-1 plasmid
or scrambled plasmid. D representative blots and bar graphs showing the levels of Pim-1 in the isolated and cultured cardiomyocytes treated
with either anti-miR-1/208a or scrambled sequence. E bar graphs showing the levels of activated caspase-3/7. Values are means ± SD. Results
of pair-wise comparison are illustrated. **P < 0.01 and ***P < 0.001 vs. non-diabetic of corresponding gender. #P < 0.05 and ##P < 0.01 vs. male diabetic.
$P < 0.05, $$P < 0.01 and $$$P < 0.001 vs. scrambled plasmid/sequence treated group of corresponding gender. All the experiments were run in triplicate
and repeated 5 independent times.
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the pro-survival protein Pim-1 in the male diabetic heart
at 8 weeks after the onset of STZ-induced diabetes. Im-
portantly, restoring the Pim-1 levels by systemic adeno-
associated viral vector gene delivery halted the progression
of diabetic cardiomyopathy [15]. In the current study, we
found that Pim-1 was downregulated within 4 weeks of
STZ-induced diabetes in the female heart, which was asso-
ciated with increased pro-apoptotic caspase-3 expression.
Studies on human heart samples also confirmed significant
downregulation of Pim-1 in female diabetic compared to
male diabetic hearts. Although it is a difficult task to trans-
late the findings from animal studies to humans, diabetes
duration for the samples collected from human diabetic
heart in our study ranged between 12 and 18 years and
based on the published evidence this relates to 12 to 16
weeks of diabetes duration in mice [38]. Of note, this was
the time point when significant difference was observed
between male and female STZ-induced diabetic mice in
most of the functional and molecular parameters.
Pim-1 is a crucial component of the signalling machin-
ery that counteracts cardiomyocyte apoptosis during the
early phase of post-ischemic healing [15,17,39,40]. This
was true in our study where restoration of Pim-1 in-
creased the survival of female diabetic cardiomyocytes.
Akt is the major mediator of Pim-1. Murasaki et al dem-
onstrated marked increase in the expression levels of
Pim-1 following overexpression of cardiomyocytes, while
knocking down Akt reduced Pim-1 [41]. Interestingly,
our results did not demonstrate any changes in the level
of Akt at 4 weeks, suggesting that early implication of
Pim-1 on survival could be Akt independent, but they
could synergise later producing more apoptosis.
Our results newly show marked upregulation of miR-1
in the female diabetic heart. MiR-1 has been well dem-
onstrated as the direct regulator of Pim-1 in the heart
independent of Akt [17] and our earlier study showed
marked improvement in the survival of male diabetic
cardiomyocytes following knockdown of miR-1 [15]. In
addition to miR-1, we also found early activation of miR-
208a in the female diabetic mice, which might also ac-
count for increased LV dilation early in the female dia-
betic heart [42]. In support of this notion, inhibition of
both miR-1 and -208a improved the survival of female
diabetic cardiomyocytes. However, the miR expression
study on human hearts did not reveal any significant dif-
ference between male and female diabetics although there
was a trend for increased expression of miR-1 in female
diabetics. This could be attributed to the long duration of
diabetes (>12 years) when samples were collected from
the patients. Another reason could be that all the patients
underwent coronary artery bypass graft surgery for ische-
mic heart disease, in contrast to the isolated cardiomyop-
athy of the mouse model. Additional in vivo studies arenecessary to understand the role of miR-1 and miR-208a
in accelerating the development of cardiomyopathy in fe-
male diabetic hearts.
In summary, our results provide novel insights into
the molecular mechanisms behind the rapid onset of
cardiomyopathy in STZ-induced female diabetic mice,
with preliminary data from human hearts supporting the
pre-clinical study results. Future studies targeted on
in vivo restoration of Pim-1 either by upregulation of
Pim-1 or by knocking-down miR-1 will provide a plat-
form for the development of gender specific treatment
to combat the disease.
Study limitations
In the present study we used STZ-induced type-1 dia-
betes model to prove our concept. Although our earlier
study has demonstrated comparable disease pattern and
progression in the type-1 and type-2 diabetic model [17],
it is essential to demonstrate if similar gender difference
exhibit in type-2 diabetes. Human data shown in this
study come from right atrial appendage samples, while
the results from animal study are from the ventricle. Al-
though Lamberts et al (personal communication, 2014)
showed no difference in the functional properties of the
trabeculae isolated from the rat atria and ventricle, fur-
ther studies will be required to confirm if the same ex-
ists in the expression pattern of Pim-1 between atria and
ventricle.
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